upper respiratory tract infections bovenste luchtwegklachten
Conditions
Interventions
Guideline adherence including prescribing wait-and-see prescriptions (WASP) will be subject of a training in 10 pharmacotherapy audit meetings (PTAMs). These 10 PTAMs (and consequently their participa
Sponsors
IVM (subsidized by ZonMw)
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients who consult their GP with URTI are in principal eligible to receive a wait-and-see prescription. Since, preferably, GPs should not prescribe antibiotics to patients with URTI, in practice only those patients for whom the GP thinks a WASP is an option will receive a WASP and only after discussing it with the patient (note: if the GP thinks the patient needs an antibiotic s/he will prescribe that antibiotic without discussing the principle of WASP). It is up to the GP to discuss a WASP with the patient and to decide whether or not to prescribe a WASP; 2. Patients of all ages will be included.
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the number of patients with URTI who filled their antibiotic prescription at the pharmacy in the 12 months before the first PTAM-meeting (pretest) and 12 months hereafter (posttest). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cccurence of complications (e.g. bronchitis and pneumonia); 2. Patients' judgement on the quality of care received for URTI. | — |
Contacts
Public ContactMarianne Meulepas
IVM, Dutch Institute for Rational Use of Medicine P.O. Box 3089
Outcome results
None listed